Creating more inclusive workplaces across the biotech sector
In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. 12 million adults of working age have hearing loss in one or both ears.
As an employer, it is essential to be prepared for conversations about hearing loss in the workplace and to know how to best support staff members who disclose theirs. As part of our partnership, RNID and the BIA are teaming up to offer valuable resources and initiatives for all BIA members. Register to:
- Book your FREE place in a remote Deaf Awareness Training session (normally £699 per session - limited spots available, book now!)
- Order a bespoke plaque featuring your company’s name in British Sign Language (BSL)
- Request bespoke employment and inclusion support, training, or partnership opportunities
RNID’s Hearing Therapeutics Initiative Network
Become part of a global cross-sector community focused on developing the hearing therapeutics of the future.
RNID’s ‘Hearing Therapeutics Initiative’ (HTI) accelerates the global development of new treatments and therapeutics to prevent and treat hearing loss and tinnitus. The HTI creates partnerships across the global hearing research ecosystem, bringing together hearing researchers, clinicians, funders, investors, and those working in biotech, pharma, and hearing device companies.
Learn more and join the HTI Network
RNID and BIA working together:
- This partnership between RNID and the BIA and its members comes at a pivotal moment in global hearing therapeutics.
- Our partnership will boost efforts to accelerate the progress being made to bring about treatments to prevent hearing loss, restore hearing for those who want it and silence tinnitus.
- To maximise impact, 100% of funds raised over the year will be restricted to RNID’s research funding.
A message from Carla
A message from Carla, who graced our gala event to share her profound journey as the mother of an extraordinary young boy named Cameron.
At only 11 years old, Cameron battles with the challenges posed by Norrie Disease, a rare genetic condition rooted in mutations within the NDP gene.
Thank you for your incredible support at the BIA’s Gala. Together, we raised an amazing £64,000 that will contribute to groundbreaking research into hearing loss, potentially transforming lives like Cameron's. With no effective cures for hearing loss, thinking about Cameron’s future sometimes feels daunting, fearing a life filled with silent darkness. However, the support you showed for RNID last week gave me a much-needed boost of hope. This isn’t just for Cameron; it’s also for the 18 million people in the UK who are deaf, have hearing loss, or tinnitus. That's why I'm delighted that RNID is this year’s BIA Charity of the Year Partner. The timing couldn’t be better, with recent advances in understanding the biology of hearing loss and tinnitus and the first clinical trials of gene therapy to restore hearing showing huge promise. This not only brings hope to those with hearing loss but also creates significant opportunities for the bioindustry—opportunities that RNID is uniquely placed to help you explore.